Sectors & Industries HealthcareDrug Manufacturers - General
Best General Drug Manufacturer Stocks to Buy Now (2026)
Top general drug manufacturer stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +28.50% per year, and are the best general drug manufacturer stocks to buy now. Learn More.

Industry: Drug Manufacturers - Gene...

Overview Zen Rating Price Value Growth Financials

Momentum Sentiment Forecast Dividends Due Diligence

General Drug Manufacturers is Zen Rated A and is the 9th ranked industry out of 145 stock market industries

Ticker	Company	Market Cap	ROE	ROA	ROCE	ROIC	D/E	Current Ratio	Gross Margin	Profit Margin	Operating Margin
BMY	BRISTOL MYERS SQUIBB CO	$130.12B	46.80%	10.30%	17.28%	19.30%	2.93	1.53	70.20%	18.90%	24.23%
LLY	ELI LILLY & CO	$1.15T	92.60%	22.00%	35.54%	32.50%	3.20	1.36	83.40%	33.50%	42.17%
ABBV	ABBVIE INC	$439.59B	-135.70%	4.70%	12.13%	16.40%	-23.58	0.81	71.50%	9.80%	17.61%
AMGN	AMGEN INC	$225.00B	89.30%	9.50%	18.47%	18.00%	7.18	1.37	69.50%	23.00%	34.01%
GILD	GILEAD SCIENCES INC	$168.47B	-16.30%	-5.80%	-2.50%	-2.50%	3.18	1.27	79.60%	-10.60%	-3.14%
MRK	MERCK & CO INC	$327.94B	6.60%	2.40%	7.54%	8.00%	2.09	1.32	73.00%	4.80%	11.56%
PFE	PFIZER INC	$149.96B	4.90%	2.10%	2.47%	3.70%	1.36	1.27	73.20%	6.80%	6.55%
GRFS	GRIFOLS SA	$5.45B	7.20%	2.00%	6.45%	6.50%	2.30	2.51	38.00%	5.30%	15.18%
AZN	ASTRAZENECA PLC	$245.68B	21.70%	9.10%	16.99%	29.20%	1.30	0.89	81.90%	17.00%	23.33%
SNY	SANOFI	$106.60B	5.70%	3.10%	6.00%	13.20%	0.86	0.99	72.80%	8.10%	11.91%
BIIB	BIOGEN INC	$30.86B	4.50%	2.80%	3.59%	7.30%	0.70	1.87	74.00%	8.30%	10.09%
JNJ	JOHNSON & JOHNSON	$628.65B	25.70%	10.60%	17.93%	34.50%	1.37	1.09	67.90%	21.50%	26.76%
GSK	GSK PLC	$100.78B	28.20%	7.80%	15.34%	20.10%	2.53	0.82	72.70%	14.50%	18.57%
NVS	NOVARTIS AG	$289.52B	29.90%	11.10%	18.74%	30.90%	1.93	0.86	74.70%	22.50%	29.85%
AMRN	AMARIN CORP PLC	$296.99M	-6.00%	-4.20%	-5.55%	-7.70%	0.41	3.67	42.00%	-14.60%	-13.71%
SCLX	SCILEX HOLDING CO	$58.59M	N/A	-164.90%	176.30%	280.10%	-2.16	0.08	59.70%	-1,239.40%	-1,083.57%
NSRX	NASUS PHARMA LTD	$29.19M	N/A	-204.70%	-208.87%	22,392.50%	0.81	2.25	N/A	N/A	N/A
OGN	ORGANON & CO	$3.59B	23.40%	1.60%	9.08%	7.40%	12.10	1.95	52.70%	3.40%	15.65%
MIRA	MIRA PHARMACEUTICALS INC	$31.05M	-450.30%	-431.80%	-104.92%	-294.40%	0.01	82.16	N/A	N/A	N/A
MDCX	MEDICUS PHARMA LTD	$18.75M	-5,695.90%	-520.00%	-2,641.77%	1,716.90%	4.52	1.22	N/A	N/A	N/A

General Drug Manufacturer Stocks FAQ

What are the best general drug manufacturer stocks to buy right now in Aug 2026?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best general drug manufacturer stocks to buy right now are:

1. Bristol Myers Squibb Co (NYSE:BMY)

Bristol Myers Squibb Co (NYSE:BMY) is the #1 top general drug manufacturer stock out of 20 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Bristol Myers Squibb Co (NYSE:BMY) is: Value: A, Growth: C, Momentum: B, Sentiment: A, Safety: B, Financials: B, and AI: B.

Bristol Myers Squibb Co (NYSE:BMY) has a Due Diligence Score of 54, which is 19 points higher than the general drug manufacturer industry average of 35.

BMY passed 19 out of 38 due diligence checks and has strong fundamentals. Bristol Myers Squibb Co has seen its stock return 36.84% over the past year, underperforming other general drug manufacturer stocks by -13 percentage points.

Bristol Myers Squibb Co has an average 1 year price target of $68.67, an upside of 7.8% from Bristol Myers Squibb Co's current stock price of $63.70.

Bristol Myers Squibb Co stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 13 analysts covering Bristol Myers Squibb Co, 61.54% have issued a Strong Buy rating, 0% have issued a Buy, 38.46% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Eli Lilly & Co (NYSE:LLY)

Eli Lilly & Co (NYSE:LLY) is the #2 top general drug manufacturer stock out of 20 with a Zen Rating of B. Stocks with a rating of B have had an average return of +17.17% per year. Learn more.

The Component Grade breakdown for Eli Lilly & Co (NYSE:LLY) is: Value: B, Growth: C, Momentum: A, Sentiment: B, Safety: C, Financials: C, and AI: B.

Eli Lilly & Co (NYSE:LLY) has a Due Diligence Score of 60, which is 25 points higher than the general drug manufacturer industry average of 35.

LLY passed 24 out of 38 due diligence checks and has strong fundamentals. Eli Lilly & Co has seen its stock return 90.84% over the past year, overperforming other general drug manufacturer stocks by 41 percentage points.

Eli Lilly & Co has an average 1 year price target of $1,340.44, an upside of 9.85% from Eli Lilly & Co's current stock price of $1,220.28.

Eli Lilly & Co stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 16 analysts covering Eli Lilly & Co, 68.75% have issued a Strong Buy rating, 25% have issued a Buy, 0% have issued a hold, while 6.25% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Abbvie (NYSE:ABBV)

Abbvie (NYSE:ABBV) is the #3 top general drug manufacturer stock out of 20 with a Zen Rating of B. Stocks with a rating of B have had an average return of +17.17% per year. Learn more.

The Component Grade breakdown for Abbvie (NYSE:ABBV) is: Value: C, Growth: B, Momentum: C, Sentiment: C, Safety: B, Financials: B, and AI: C.

Abbvie (NYSE:ABBV) has a Due Diligence Score of 38, which is 3 points higher than the general drug manufacturer industry average of 35.

ABBV passed 14 out of 38 due diligence checks and has average fundamentals. Abbvie has seen its stock return 25.23% over the past year, underperforming other general drug manufacturer stocks by -24 percentage points.

Abbvie has an average 1 year price target of $277.40, an upside of 11.51% from Abbvie's current stock price of $248.76.

Abbvie stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 15 analysts covering Abbvie, 60% have issued a Strong Buy rating, 20% have issued a Buy, 20% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the general drug manufacturer stocks with highest dividends?

Out of 14 general drug manufacturer stocks that have issued dividends in the past year, the 3 general drug manufacturer stocks with the highest dividend yields are:

1. Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE) has an annual dividend yield of 6.54%, which is 4 percentage points higher than the general drug manufacturer industry average of 2.68%. Pfizer's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Pfizer's dividend has shown consistent growth over the last 10 years.

Pfizer's dividend payout ratio of 226.3% indicates that its high dividend yield might not be sustainable for the long-term.

2. Sanofi (NASDAQ:SNY)

Sanofi (NASDAQ:SNY) has an annual dividend yield of 4.04%, which is 1 percentage points higher than the general drug manufacturer industry average of 2.68%. Sanofi's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Sanofi's dividend has shown consistent growth over the last 10 years.

Sanofi's dividend payout ratio of 94.5% indicates that its high dividend yield might not be sustainable for the long-term.

3. Bristol Myers Squibb Co (NYSE:BMY)

Bristol Myers Squibb Co (NYSE:BMY) has an annual dividend yield of 3.94%, which is 1 percentage points higher than the general drug manufacturer industry average of 2.68%. Bristol Myers Squibb Co's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Bristol Myers Squibb Co's dividend has shown consistent growth over the last 10 years.

Bristol Myers Squibb Co's dividend payout ratio of 55.2% indicates that its high dividend yield is sustainable for the long-term.

Why are general drug manufacturer stocks up?

General drug manufacturer stocks were up 0.36% in the last day, and up 2.29% over the last week.

We couldn't find a catalyst for why general drug manufacturer stocks are up.

What are the most undervalued general drug manufacturer stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued general drug manufacturer stocks right now are:

1. Bristol Myers Squibb Co (NYSE:BMY)

Bristol Myers Squibb Co (NYSE:BMY) is the most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Bristol Myers Squibb Co has a valuation score of 43, which is 14 points higher than the general drug manufacturer industry average of 29. It passed 3 out of 7 valuation due diligence checks.

Bristol Myers Squibb Co's stock has gained 36.84% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -13 percentage points.

2. Grifols Sa (NASDAQ:GRFS)

Grifols Sa (NASDAQ:GRFS) is the second most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Grifols Sa has a valuation score of 71, which is 42 points higher than the general drug manufacturer industry average of 29. It passed 5 out of 7 valuation due diligence checks.

Grifols Sa's stock has dropped -25.19% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -75 percentage points.

3. Biogen (NASDAQ:BIIB)

Biogen (NASDAQ:BIIB) is the third most undervalued general drug manufacturer stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Biogen has a valuation score of 71, which is 42 points higher than the general drug manufacturer industry average of 29. It passed 5 out of 7 valuation due diligence checks.

Biogen's stock has gained 62% in the past year. It has overperformed other stocks in the general drug manufacturer industry by 12 percentage points.

Are general drug manufacturer stocks a good buy now?

50% of general drug manufacturer stocks rated by analysts are a strong buy right now. On average, analysts expect general drug manufacturer stocks to rise by 8.01% over the next year.

6.25% of general drug manufacturer stocks have a Zen Rating of A (Strong Buy), 37.5% of general drug manufacturer stocks are rated B (Buy), 50% are rated C (Hold), 6.25% are rated D (Sell), and 0% are rated F (Strong Sell).

What is the average p/e ratio of the drug manufacturers - general industry?

The average P/E ratio of the drug manufacturers - general industry is 38.14x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.

General Drug Manufacturer Stocks FAQ

1. Bristol Myers Squibb Co (NYSE:BMY)

2. Eli Lilly & Co (NYSE:LLY)

3. Abbvie (NYSE:ABBV)

1. Pfizer (NYSE:PFE)

2. Sanofi (NASDAQ:SNY)

3. Bristol Myers Squibb Co (NYSE:BMY)

1. Bristol Myers Squibb Co (NYSE:BMY)

2. Grifols Sa (NASDAQ:GRFS)

3. Biogen (NASDAQ:BIIB)

Company

Stock Tools

Stock Ideas